Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Listed as NCT04815902, this PHASE1/PHASE2 trial focuses on Osteoarthritis, Knee and remains ongoing. Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), it has been updated 11 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Apr 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Steadman Philippon Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .